Source comparison
PT-141 Nasal vs Subcutaneous: Administration Route Comparison
Subcutaneous Injection ~100% (no first-pass loss) 60 minutes 4–6 hours above threshold High. Consistent absorption across subjects Injection site erythema (8–10%), transient nausea (15–20%) Preferred for studies requiring reproducible dosing and tight plasma c
This comparison does not assign a generated winner or score.
- Subcutaneous Injection
- ~100% (no first-pass loss)
- 60 minutes
- 4–6 hours above threshold
- High. Consistent absorption across subjects
- Injection site erythema (8–10%), transient nausea (15–20%)
- Preferred for studies requiring reproducible dosing and tight plasma curves. Highest bioavailability and lowest inter-subject variance
- Intranasal Spray
- 3–5% (mucosal barrier + hepatic metabolism)
- 90–120 minutes
- 2.5–4 hours above threshold
- Moderate. Absorption varies with nasal cycle, hydration, anatomy
- Nasal congestion (25–30%), rhinorrhea (10–15%), epistaxis (5%)
- Suitable for studies tolerating higher variance. Convenience does not offset 40–60% lower plasma concentration
- Comparison Notes
- Subcutaneous delivers 15–30× higher effective dose per mg administered
- Subcutaneous onset 30–50% faster
- Subcutaneous maintains therapeutic levels 30–60% longer
- Nasal absorption coefficient of variation 40–60% vs 15–20% for subcutaneous
- Side effect profile shifts from local (nasal mucosa) to systemic (nausea, flushing)
- Route selection should prioritize study design requirements (precision vs. convenience). Most published research uses subcutaneous for this reason